Yousef Zakharia, MD | Authors

Articles

Evaluating Future Steps for Investigating Seleno-L-Methionine in RCC

May 28, 2020

Yousef Zakharia, MD, discusses the next steps after the phase 1 trial of seleno-L-methionine in combination with axitinib as treatment of adult patients with previously treated or relapsed clear cell renal cell carcinoma.

Promising Efficacy and Safety With Seleno-L-Methionine Plus Axitinib in ccRCC

May 16, 2020

Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.

Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma

April 06, 2017

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.